[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533285":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":58,"collaborators":18,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":18,"studyType":74,"phases":75,"briefSummary":78,"conditions":79,"keywords":18,"overallStatus":42,"whyStopped":18,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Johns Hopkins All Children's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Azithromycin Intervention","EXPERIMENTAL","Participants in this arm will receive Azithromycin 10mg\u002Fkg\u002Fdose (max dose 500mg) once daily for 3 days.",[13],"Drug: Azithromycin",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard Care","NO_INTERVENTION","Participants will receive standard care without Azithromycin.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Azithromycin","10mg\u002Fkg\u002Fdose (max dose 500mg) once daily for 3 days",[9],[26],"Zithromax",[28],{"name":29,"affiliation":5,"role":30},"Anthony A Sochet, MD","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":18,"email":35},"CONTACT","727-487-3711","Sochet@jhmi.edu",{"name":37,"role":33,"phone":38,"phoneExt":18,"email":39},"Alexa R Roberts, MD","602-526-4397","arober77@jhmi.edu",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","St. Petersburg","Florida","33701","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-82.67927,27.77086,{"lat":52,"lon":51},[55],{"name":29,"role":33,"phone":56,"phoneExt":18,"email":57},"727-767-2912","sochet@jhmi.edu",{"type":59,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100533285","phase-2-azithromycin-for-critical-asthma---pediatrics-100533285",false,"NCT06223828","Azithromycin for Critical Asthma - Pediatrics","Azithromycin as Immunomodulation Among Children Hospitalized for Critical Asthma: A Prospective, Open-Label, Non-Randomized, Interventional Study With Parallel Biospecimen Banking","CR-AZI Kids","Inclusion criteria\n\n* Age 3-17 years\n* Admission to the PICU\n* Primary diagnosis of critical asthma\n* Prescription for continuous inhaled beta-agonist therapy and\u002For intravenous (IV) beta-agonist therapy\n* Prescription for intravenous systemic corticosteroids\n\nExclusion criteria\n\n* Critical Congenital Heart Disease Unrepaired\n* Tracheostomy Dependence at Admission\n* Ongoing Exposure to Azithromycin or Macrolide Antibiotics for any indication\n* Past Medical History of Prolonged QT Syndrome or Arrhythmias\n* Concomitant respiratory pathology including Acute Chest Syndrome, Interstitial Lung Disease, Cystic Fibrosis, and pulmonary hypertension","ALL","3 Years","17 Years",{"count":72,"type":73},100,"ESTIMATED","INTERVENTIONAL",[76,77],"PHASE2","PHASE3","The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.",[80,81],"Pediatric Asthma","Critical Illness","2025-12-16",{"date":84,"type":85},"2025-12-17","ACTUAL",{"date":87,"type":85},"2024-04-02",{"date":89,"type":73},"2026-12-31",{"name":5,"class":6},1]